

EXHIBIT E



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

MDELAPAZ@FULBRIGHT.COM
DIRECT DIAL: (512) 536-5639

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

November 8, 2004

VIA FEDERAL EXPRESS

Prof. T. Mukhopadhyay, Ph.D.
National Center for Genome Studies and Research
Sector 14,
Panjab University
Chandigarh 160014
INDIA

Re: *U.S. Patent Application No. 10/043,877 entitled "ANTIHELMINTHIC DRUGS AS A TREATMENT FOR HYPERPROLIFERATIVE DISEASES" – Tapas Mukhopadhyay et al.*
OurRef. INRP:095US; Client Ref. MDA99-067

Dear Dr. Mukhopadhyay:

As per my recent email correspondence to you, enclosed is a hardcopy of the draft declaration that was attached to the email.

The response to the most recent Office Action was due on Oct. 28, 2004. We filed the response without an executed declaration, indicating that the executed declaration would be forthcoming in a supplemental response. Please review the enclosed declaration.

If, after review of the declaration, you find that it is in order and you can sign the declaration in view of the certification in the last paragraph, please print out a copy, execute and date the declaration, and fax it to me. Should you have minor corrections to the declaration, you may make them in ink and sign and initial each correction in the margin. Should you have major corrections, you may contact me by fax, phone or email to discuss these matters.

Once we receive your signature, we can proceed to file the executed declaration in a supplemental response to the Office Action. If you have any further questions or comments about this letter, or about progress of the present application, please feel free to contact me.

Sincerely,

Monica A. De La Paz, MD, JD

MAD/vv
Enclosure

25471269.1 / 10200175

Prof. T. Mukhopadhyay, Ph.D.
November 8, 2004
Page 2

cc: David L. Parker, Esq. (w/o encl.)
Sunil Chada, Ph.D. (w/o encl.)
Steven L. Highlander, Esq. (w/o encl.)